Loading…
Suzhou-based Chinese biopharmaceutical company, per its industry classification; specific pipeline not independently confirmed.
Suzhou-based Chinese biopharmaceutical company, per its industry classification; specific pipeline not independently confirmed.
Moat: none
Headquarters: Suzhou, China · Employees: 85
Size LongBio Pharma (Suzhou) (1779.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $510M, the 741st largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$51.35 on 18 Nov 2026.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | HK$0 | HK$0 | HK$0 | HK$0 |
| Revenue growth | — | — | — | — |
| Gross profit | -HK$8.86M | -HK$8.83M | -HK$7.86M | -HK$6.20M |
| EBITDA | -HK$234M | -HK$167M | -HK$111M | -HK$83.8M |
| Net income | -HK$243M | -HK$190M | -HK$149M | -HK$106M |
| Free cash flow | n/a | -HK$137M | -HK$118M | -HK$70.0M |
| Capital expenditure | n/a | HK$4.76M | HK$6.66M | HK$2.73M |
| Total debt | n/a | HK$42.2M | HK$476M | HK$347M |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1779.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -30.4% | -9.5% | 2nd lowest of 21 |
| Distance from 52-week high | -69.0% | -45.2% | 3rd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $510M | n/a | n/a | n/a | n/a | n/a | n/a |
| Valneva VLA.PA | France | $508M | -6% | -27% | -87% | 3.9× | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $518M | -20% | -1% | -13% | 6.2× | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $501M | -28% | +4% | 8% | 7.5× | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $494M | -19% | -17% | 0% | 6.2× | 29.4% | +7.0% |
| Liaoning Dingjide Petrochemical 603255.SS | China | $490M | -24% | +70% | 5% | 5.2× | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $488M | +24% | -47% | -17,694% | 8,281.1× | n/a | n/a |
| Crescent Biopharma CBIO | United States | $482M | -34% | n/a | -1,217% | 13.3× | n/a | n/a |
| Frontage 1521.HK | Hong Kong | $542M | +113% | +10% | 8% | 2.3× | 14.3% | +15.4% |
| TaiMed Biologics 4147.TWO | Taiwan | $480M | +19% | +7% | -31% | 22.7× | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +9% | n/a | n/a | n/a | n/a | n/a |
| Neurogene NGNE | United States | $479M | -14% | -100% | n/a | n/a | n/a | n/a |
| Climb Bio CLYM | United States | $546M | -12% | n/a | n/a | n/a | n/a | n/a |
| Wave Life Sciences WVE | United States | $546M | -55% | -35% | -321% | 2.2× | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $471M | +37% | +71% | 5% | 6.4× | 58.8% | +204.7% |
| Hvsen Biotechnology 300871.SZ | China | $553M | -22% | +2% | 17% | 2.3× | n/a | n/a |
| Sana Biotechnology SANA | United States | $554M | -41% | n/a | n/a | n/a | n/a | n/a |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $470M | n/a | n/a | n/a | n/a | n/a | n/a |
| Kamada KMDA | United States | $465M | +3% | +5% | 15% | 2.0× | 5.0% | +6.5% |
| Boji Medical Technology 300404.SZ | China | $561M | -6% | +32% | 4% | 3.4× | 31.9% | +27.2% |
| DiaMedica Therapeutics DMAC | United States | $463M | +50% | n/a | n/a | n/a | n/a | n/a |